48Hour Discovery Enters into Agreement with TumorGenesis

Edmonton-based start-up to develop personalized cancer therapy models: EDMONTON (March 29, 2018)–48Hour Discovery Inc. (48HD) announced today that they have signed an agreement with Precision Therapeutics Inc. (NASDAQ:AIPT) and its wholly owned subsidiary, TumorGenesis Inc. 48HD will grant access to its patented molecular discovery technology, enabling TumorGenesis Inc. to develop precision cancer therapy models. 48HD uses genetic encoding of small molecule display libraries for rapid discovery of novel molecular interactions. 48HD will apply the technology to discover patient-specific biomolecules for the development of individualized health care solutions. “We are excited to be a part of this cutting-edge technology enterprise for… read more >>